NASDAQ:TRIL Trillium Therapeutics (TRIL) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free TRIL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$18.44▼$18.4450-Day Range$17.50▼$18.4452-Week Range$5.80▼$20.96Volume8 shsAverage Volume1.87 million shsMarket Capitalization$1.94 billionP/E Ratio29.74Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Trillium Therapeutics alerts: Email Address Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Trillium Therapeutics Stock (NASDAQ:TRIL)Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Read More Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details TRIL Stock News HeadlinesNovember 10, 2023 | businesswire.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 8, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsMay 3, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 31, 2023 | uk.finance.yahoo.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodApril 26, 2023 | msn.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 4, 2023 | uk.finance.yahoo.comLeukemia Therapeutics Global Market Report 2023March 28, 2023 | finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckOctober 19, 2022 | nz.finance.yahoo.comFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaMay 3, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 14, 2022 | seekingalpha.comCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentSeptember 12, 2022 | nz.finance.yahoo.comZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsAugust 17, 2022 | seekingalpha.comPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is NeededJune 22, 2022 | markets.businessinsider.com10 Psychedelics CEOs To Pay Attention To In 2022May 20, 2022 | edition.cnn.comPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?March 20, 2022 | nasdaq.com3 Dividend Stocks That We'd Buy Without Any HesitationMarch 17, 2022 | stockhouse.comMindset Pharma CEO, James Lanthier, Issues Letter to ShareholdersFebruary 17, 2022 | finanznachrichten.deNeonMind Biosciences Inc.: NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, OntarioDecember 14, 2021 | au.finance.yahoo.comCD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 - ResearchAndMarkets.comDecember 14, 2021 | law360.com3 Firms Draw Up Pfizer's $6.7B Arena Pharmaceuticals BuyOctober 25, 2021 | finance.yahoo.comIs Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?October 16, 2021 | msn.com2 Top Healthcare Stocks That Could Be Bought Out in 2022October 13, 2021 | msn.comBRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14September 22, 2021 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the FirmSeptember 11, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRILSeptember 9, 2021 | benzinga.comMoore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law FirmSeptember 7, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and SIC Shareholders About Its Ongoing InvestigationsSeptember 4, 2021 | finance.yahoo.comWhy Investors Should Love Pfizer's Acquisition of TrilliumSee More Headlines Receive TRIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/18/2021Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRIL CUSIPN/A CIK1616212 Webwww.trilliumtherapeutics.com Phone(416) 595-0627FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.62 Trailing P/E Ratio29.74 Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,350,000.00 Net MarginsN/A Pretax Margin-113,720.92% Return on Equity-23.31% Return on Assets-18.66% Debt Debt-to-Equity RatioN/A Current Ratio19.82 Quick Ratio19.82 Sales & Book Value Annual Sales$150,000.00 Price / Sales12,907.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book7.20Miscellaneous Outstanding Shares104,995,000Free Float95,440,000Market Cap$1.94 billion OptionableOptionable Beta2.08 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesJan SkvarkaPresident, Chief Executive Officer & DirectorJames T. ParsonsChief Financial OfficerRobert A. UgerChief Scientific OfficerKathleen LargeSenior Vice President-Clinical OperationsIngmar BrunsChief Medical OfficerKey CompetitorsNewAmsterdam PharmaNASDAQ:NAMSRocket PharmaceuticalsNASDAQ:RCKTAvidity BiosciencesNASDAQ:RNAGalapagosNASDAQ:GLPGAmneal PharmaceuticalsNASDAQ:AMRXView All Competitors TRIL Stock Analysis - Frequently Asked Questions How were Trillium Therapeutics' earnings last quarter? Trillium Therapeutics Inc. (NASDAQ:TRIL) released its quarterly earnings data on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK). This page (NASDAQ:TRIL) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsUrgent alert: open this for a huge profit potentialTimothy SykesThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
